<SEC-DOCUMENT>0000950170-21-001535.txt : 20210823
<SEC-HEADER>0000950170-21-001535.hdr.sgml : 20210823
<ACCEPTANCE-DATETIME>20210823080520
ACCESSION NUMBER:		0000950170-21-001535
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20210819
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Termination of a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210823
DATE AS OF CHANGE:		20210823

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Viracta Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001061027
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943295878
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51531
		FILM NUMBER:		211195404

	BUSINESS ADDRESS:	
		STREET 1:		2533 S COAST HWY 101
		STREET 2:		SUITE 210
		CITY:			CARDIFF
		STATE:			CA
		ZIP:			92007
		BUSINESS PHONE:		858-400-8470

	MAIL ADDRESS:	
		STREET 1:		2533 S COAST HWY 101
		STREET 2:		SUITE 210
		CITY:			CARDIFF
		STATE:			CA
		ZIP:			92007

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MOSAIC PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19980709

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUNESIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19980501
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>virx-20210819.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2021-08-23T05:45:54.1142+00:00 -->
<!-- Copyright (c) 2021 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:virx="http://viracta.com/20210819">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body>
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_99a448ca-4632-4afe-a3a6-7c3efd7aa1b3" name="dei:EntityRegistrantName" contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24">Viracta Therapeutics, Inc.</ix:nonNumeric><ix:nonNumeric id="F_c6547e63-7c8b-43a5-bdbb-c242e5b5cb3d" name="dei:AmendmentFlag" contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24">false</ix:nonNumeric><ix:nonNumeric id="F_82bc508a-43ab-4a58-a008-b41d3a6e97ec" name="dei:EntityCentralIndexKey" contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24">0001061027</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="virx-20210819.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001061027</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-19</xbrli:startDate><xbrli:endDate>2021-08-19</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <p style="border-top:2.250pt double rgba(0,0,0,1);text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.75pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">UNITED STATES<br />SECURITIES AND EXCHANGE COMMISSION<br /></span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.2pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">FORM </span><span style="font-size:18.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b2c24b6f-89ae-47ea-b8ab-897f9dcf84a0" contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24" name="dei:DocumentType"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.2pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">CURRENT REPORT</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.02986111111111111in;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Date of Report (Date of earliest event reported): </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fb0b928d-6563-47fd-b1f3-a7a2684dc135" contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">August 19, 2021</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:24.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_99a448ca-4632-4afe-a3a6-7c3efd7aa1b3;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:24.0pt;font-family:Times New Roman;">VIRACTA THERAPEUTICS, INC.</span></span></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Exact name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:18.0%;"></td>
    <td style="width:41.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aa31a73f-20f5-4da3-9186-45e7b54c0a92" contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3cad98d0-6984-4412-8548-01ef495b85fc" contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24" name="dei:EntityFileNumber"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">000-51531</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8db97ff1-0584-4b07-9ee2-9afee9f1f516" contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24" name="dei:EntityTaxIdentificationNumber"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">94-3295878</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(State or Other Jurisdiction<br />of Incorporation)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Commission File Number)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(IRS Employer<br />Identification No.)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_034c6ffd-922c-4189-84d6-7656116b2b43" contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24" name="dei:EntityAddressAddressLine1"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2533 S. Coast Hwy. 101, Suite 210</span></ix:nonNumeric></span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1ad26db1-5185-4a4e-a243-f257c2c65bf9" contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24" name="dei:EntityAddressCityOrTown"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cardiff</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f0db7117-e876-46aa-bcaa-df46b6b3af4a" contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">California</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6b373f51-15bc-40f2-8694-d53d815c3f70" contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24" name="dei:EntityAddressPostalZipCode"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">92007</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Address of Principal Executive Offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.125in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.02986111111111111in;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Registrant&#x2019;s Telephone Number, Including Area Code:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e4d75748-d9d7-4287-8e6b-363498a97a44" contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24" name="dei:CityAreaCode"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(858)</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_daaff47f-11c3-48ac-afd5-7b2f2a609e24" contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24" name="dei:LocalPhoneNumber"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">400-8470</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.125in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:9.35pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.35pt;line-height:1.3;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:9.0pt;line-height:1.3;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6b4f1169-4b8e-48a4-ae41-47e71381c7c7" contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;line-height:1.3;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2f4b2d15-0bd8-473d-9ec2-b11435062021" contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;line-height:1.3;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_16917a3e-46d6-4414-9079-3e00b51b964b" contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;line-height:1.3;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_418f36d1-7417-4e9f-9f94-6e9e8e1236c6" contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:9.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:1px solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><br />Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.011pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:1px solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Trading<br />Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.011pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:1px solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><br />Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d99df070-29b0-4674-b5fe-1b71a3df6634" contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24" name="dei:Security12bTitle"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common Stock,  par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1faa20b5-7988-4f69-8a79-841d82155865" contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24" name="dei:TradingSymbol"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VIRX</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1c82aff4-357f-41c4-86d3-1a334d50a202" contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The NASDAQ Stock Market LLC</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#x202f;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#x202f;240.12b-2 of this chapter).</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Emerging growth company </span><span style="font-size:10.0pt;"><ix:nonNumeric id="F_ac32db22-e2e1-4153-b8b4-a2aaebd80b5e" contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:1.3;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 1.01 Entry into a Material Definitive Agreement.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On August 19, 2021, Viracta Therapeutics, Inc., through its wholly owned subsidiary, Viracta Subsidiary, Inc., (collectively, &#x201c;Viracta&#x201d;) and Shenzhen Salubris Pharmaceutical Co. Ltd. (&#x201c;Salubris&#x201d;) entered into a Mutual Termination Agreement, effective August 20, 2021 (the &#x201c;Termination Agreement&#x201d;), pursuant to which the parties agreed to terminate the exclusive collaboration and license agreement entered into by the parties on November 30, 2018 (the &#x201c;License Agreement), pursuant to which Viracta had granted Salubris an exclusive license, with the right to grant sublicenses, to Viracta&#x2019;s patent and know-how rights to develop and commercialize nanatinostat in combination with an antiviral drug, such as valganciclovir, for treatment, prevention, or diagnosis of virus-associated malignancies in humans and non-humans in the Republic of China, excluding Hong Kong, Macau, and Taiwan.&#160; Under the terms of the Termination Agreement, Viracta paid Salubris a payment in the amount of $4,000,000 USD on the effective date of the Termination Agreement. Pursuant to the Termination Agreement, all licenses granted by Viracta to Salubris automatically terminated, and Salubris shall use commercially reasonable efforts to seek an orderly transition of the development and commercialization of&#160; Viracta&#x2019;s technology, including the related data and regulatory filings, to Viracta.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The foregoing description of the Termination Agreement does not purport to be complete and is qualified in its entirety by reference to the text of the Termination Agreement, a copy of which is filed hereto as Exhibit 10.1 with this Current Report on Form 8-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 1.02 Termination of a Material Definitive Agreement.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information contained in Item 1.01 of this Current Report on Form 8-K with respect to the termination of the License Agreement is incorporated by reference herein and made a part hereof.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 8.01 Other Events.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On August 23, 2021, Viracta issued a &#160;press release announcing entry into the Termination Agreement. A copy of such press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(d) Exhibits</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:6.176%;"></td>
    <td style="width:4.843%;"></td>
    <td style="width:88.981%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:1.0pt;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#160;&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td>
   </tr>
   <tr style="height:4.3pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="virx-20210819ex10_1.htm"><span style="color:rgba(0,0,255,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Mutual Termination Agreement, by and between Viracta Subsidiary, Inc. and Shenzhen Salubris Pharmaceutical Co. Ltd.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="virx-20210819ex99_1.htm"><span style="color:rgba(0,0,255,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Press Release, dated August 23, 2021</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SIGNATURES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6.0%;"></td>
    <td style="width:44.0%;"></td>
    <td style="width:4.0%;"></td>
    <td style="width:46.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;line-height:1.3;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Viracta Therapeutics, Inc.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">August 23, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:1px solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Daniel Chevallard</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.7pt;line-height:1.3;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Daniel Chevallard<br />Chief Operating Officer and Chief Financial Officer</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>virx-20210819ex10_1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html>
 <head>
  <title>EX-10.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">MUTUAL TERMINATION AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">THIS MUTUAL TERMINATION AGREEMENT (&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Agreement</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) is made and entered into this 20</font><font style="color:rgba(0,0,0,1);font-weight:normal;vertical-align:top;font-size:8.04pt;font-family:Times New Roman;">th</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> day of August, 2021 (&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Effective Date</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), by and between Viracta Subsidiary, Inc. (formerly Viracta Therapeutics, Inc.), a Delaware corporation (&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Viracta</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), and Salubris Pharmaceutical Co. Ltd., a company organized under the laws of the People&#x2019;s Republic of China (&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Salubris</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">WHEREAS, Viracta and Salubris are parties to that certain Exclusive Collaboration and License Agreement, effective November 30, 2018 (&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Original Agreement</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;); and</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">WHEREAS, Viracta and Salubris have mutually agreed to terminate the Original Agreement, on the terms and conditions set forth herein;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">NOW, THEREFORE, in consideration of the foregoing recitals and the promises contained herein, the parties hereto agree as follows:</font></p>
  <div style="text-indent:6.667%;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">1.</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Payment</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Within two (2) business days of the Effective Date, Viracta shall pay to Salubris in cash the amount of four million US dollars ($4,000,000.00) wire transfer in immediately available funds to an account designated by Salubris. </font></div></div>
  <div style="text-indent:6.667%;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">2.</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Termination</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Effective as of the Effective Date, notwithstanding the provisions set forth in the Original Agreement, Salubris and Viracta agree that the Original Agreement shall be and is hereby deemed terminated and of no further force and effect.  Viracta and Salubris further agree that, notwithstanding the provisions of Section 14.7 of the Original Agreement, only the following provisions of the Original Agreement shall survive termination: Section 2.5 (No Implied License), and Sections 14.4(a), (b) and (d) (Termination, in each case to the extent applicable), 14.5 (Confidential Information), 14.6 (Rights in Bankruptcy), and Articles 1 (Definitions), 12 (Indemnification), 13 (Confidentiality), 15 (Dispute Resolution), and 16 (Miscellaneous).  </font></div></div>
  <div style="text-indent:6.667%;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">3.</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Effects of Termination</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Following the termination on the Effective Date, the termination provisions set forth in Section 14.4 of the Original Agreement shall apply.  In addition, within thirty (30) days of the Effective Date, Salubris shall transfer or cause to be transferred to Viracta, at Salubris&#x2019; expense, all Data (as defined in the Original Agreement) and all Regulatory Filings (as defined in the Original Agreement), if any, in Salubris&#x2019; reasonable control.  Salubris shall use commercially reasonable efforts and shall execute all documents reasonably necessary to effectuate a transfer and assignment of such Data and Regulatory Filings to Viracta.  Following such transfer, all such Data shall be the sole and exclusive property of Viracta.  Following the termination, Salubris shall have no rights to any Data, whether created by Salubris, Viracta or jointly by the parties. Promptly following the Effective Date, at Viracta&#x2019;s option, Salubris will either return to Viracta or destroy any CMC material in Salubris&#x2019; possession.  </font></div></div>
  <div style="text-indent:6.667%;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">4.</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Mutual Release</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Effective upon the Effective Date, each of Viracta and Salubris, on behalf of themselves and their respective affiliates, and each of their respective directors, officers, shareholders, members, employees and agents, and each of their respective heirs, administrators, successors and assigns (with respect to each party, collectively, a &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Group</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) hereby releases, waives, and forever discharges the other party and all of its affiliates and each of their respective directors, </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">	-</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <div style="margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.5in;"><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">officers, shareholders, members, employees and agents, and each of their respective heirs, administrators, successors and assigns (collectively, the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Releasees</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) from any and all claims, causes of action, suits, debts, demands, agreements, and promises, of whatever nature or kind, at law or in equity, such party or any other member of its Group now has, ever had or, but for this release, hereafter would or could have, against any Releasee, whether known or unknown, fixed or contingent, as a result of, arising directly or indirectly from or relating to (a)&#160;the Original Agreement based on occurrences on or before the Effective Date, or (b)&#160;any matter, negotiation, conversation, agreement, tort, action, inaction, disclosure, omission, event, or other occurrence, in each case, occurring at any time on or prior to the Effective Date, and (c)&#160;any and all liabilities, losses, costs and expenses related to any of the foregoing; provided, however, that it is understood that the foregoing release shall not apply to each party&#x2019;s rights and obligations set forth in Sections 1 through 3 above.</font></div></div>
  <div style="text-indent:6.667%;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">5.</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Mutual Representations and Warranties</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. Each Party hereby represents and warrants to the other Party as follows, as of the Effective Date:</font></div></div>
  <div style="text-indent:13.333%;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:1.0in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.0in;">(a)</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">it is a company or corporation duly organized, validly existing, and in good standing under the laws of the jurisdiction in which it is incorporated;</font></div></div>
  <div style="text-indent:13.333%;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:1.0in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.0in;">(b)</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">it has the corporate power and authority and the legal right to enter into this Agreement and perform its obligations hereunder;</font></div></div>
  <div style="text-indent:13.333%;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:1.0in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.0in;">(c)</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">it has taken all necessary corporate action on its part required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder and the consummation of the transactions contemplated hereby; and</font></div></div>
  <div style="text-indent:13.333%;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:1.0in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.0in;">(d)</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, and binding obligation of such Party that is enforceable against it in accordance with its terms.</font></div></div>
  <div style="text-indent:6.667%;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">6.</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Additional Representations and Warranties of Salubris</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. Salubris hereby represents and warrants to Viracta as follows, as of the Effective Date:</font></div></div>
  <div style="text-indent:13.333%;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:1.0in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.0in;">(e)</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Other than the Data and Regulatory Filings being transferred to Viracta pursuant to this Agreement, there are no Know-How or Patent Rights owned or controlled by Salubris reasonably useful or necessary for the research, Development, manufacture, preparation, use or Commercialization of the Drug Candidate or the Products in the Field; and</font></div></div>
  <div style="text-indent:13.333%;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:1.0in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.0in;">(f)</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Salubris has not granted any liens, security interests or other encumbrances on the Licensed Technology. </font></div></div>
  <div style="text-indent:6.667%;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">7.</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">No Disparagement</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Each of Viracta and Salubris agrees that it will not in any way disparage the other party or any related companies, or their respective current or former officers, agents, directors, supervisors, shareholders, employees, attorneys, representatives, successors or assigns.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">	-</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <div style="text-indent:6.667%;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">8.</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Publicity; Public Disclosures</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. The Parties agree that Viracta may issue a press release substantially in a form agreed by the Parties and attached to this Agreement as Exhibit A announcing the signature of this Agreement at or shortly after the Effective Date within the time period as required by relevant securities laws. It is understood that each Party may desire or be required to issue subsequent disclosures relating to this Agreement or activities hereunder. Either Party may make such disclosures to the SEC or other applicable agency as it determines, based on advice of counsel, is reasonably necessary to comply with Applicable Laws or for appropriate market disclosure. Each Party shall have the right to make any such filing as it reasonably determines necessary under Applicable Laws. In addition, following the initial press release by Viracta announcing this Agreement, either Party shall be free to disclose, without the other Party&#x2019;s prior written consent, the existence of this Agreement, the identity of the other Party and those terms of the Agreement which have already been publicly disclosed in accordance with this Section 8.</font></div></div>
  <div style="text-indent:6.667%;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">9.</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Governing Law</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  This Agreement shall be construed in accordance with and governed by the laws of Hong Kong, without regard to the conflict of law principles thereof.</font></div></div>
  <div style="text-indent:6.667%;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">10.</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Waiver; Amendment</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  No waiver by any party of any breach of any term or provision of this Agreement shall be construed to be, nor be, a waiver of any preceding, concurrent or succeeding breach of this Agreement or of any other term or provision of this Agreement.  No waiver shall be binding on the part of any party unless set forth in a writing signed by such party.  This Agreement may not be modified except by a written agreement signed by an authorized representative of each party.</font></div></div>
  <div style="text-indent:6.667%;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">11.</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Entire Agreement</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  This Agreement contains all of the terms and conditions agreed upon by the parties regarding the subject matter of this Agreement and supersedes and replaces any and all prior or contemporaneous agreements, promises, negotiations, or representations, either oral or written, concerning the subject matter of this Agreement.</font></div></div>
  <div style="text-indent:6.667%;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">12.</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Successors and Assigns</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  This Agreement shall be binding upon the parties hereto and upon their heirs, administrators, representatives, executors, successors, and assigns, and shall inure to the benefit of said parties and each of their respective heirs, administrators, representatives, executors, successors, and assigns.</font></div></div>
  <div style="text-indent:6.667%;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">13.</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Counterparts</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  This Agreement may be executed in two (2) or more counterparts, in original, facsimile, PDF, or other electronic format, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">	-</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">IN WITNESS WHEREOF, the parties have executed this Termination Agreement on the Effective Date.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">SALUBRIS PHARMACEUTICAL CO. LTD.<br></font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">By:    </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">/s/ Kevin Ye_____________</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Title: _</font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">CEO</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">___________________</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">VIRACTA SUBSIDIARY, INC.<br></font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">By:  </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">_/s/ Ivor Royston</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">________	</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Title:  _</font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">CEO</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">________________</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">	-</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">4</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">EXHIBIT A</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Viracta Press Release</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">	-</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">5</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>virx-20210819ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">Exhibit 99.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Calibri;">Viracta Therapeutics Reacquires Exclusive Development and Commercialization Rights for its All-Oral Combination Therapy in China</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;font-style:italic;">Viracta now controls global rights to its all-oral combination regimen of nanatinostat and valganciclovir</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;font-style:italic;">   </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;font-style:italic;">PR Newswire, San Diego, August 23, 2021 &#x2013; </font><font><font style="font-weight:normal;font-size:12.0pt;font-family:Calibri;">Viracta</font></font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;"> Therapeutics, Inc.  (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that it has reacquired the exclusive rights to develop and commercialize its all-oral combination product candidate in the People&#x2019;s Republic of China previously licensed to Shenzhen Salubris Pharmaceuticals Co., Ltd. (Salubris).  Pursuant to the mutual termination agreement between Viracta and Salubris, all development and commercialization rights under the license have been returned to Viracta in exchange for a $4.0 million cash payment to Salubris.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">&#x201c;We thank the Salubris team for their support of Viracta and their collaborative contributions.  As Viracta&#x2019;s strategic focus remains in precision oncology and Salubris focuses their development efforts on cardiovascular and related disease areas, we agreed the reversion of these rights to Viracta was in the best interest of patients,&#x201d; said Ivor Royston, M.D., President and Chief Executive Officer of Viracta.  &#x201c;China represents an important geographical region for the treatment of patients with EBV-associated cancers.  We believe regaining the development and commercial rights in China will enable Viracta to expand our global development strategy and has the potential to unlock significant, long-term and unencumbered value to our shareholders.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">Viracta&#x2019;s combination therapy of nanatinostat, its proprietary investigational drug, and valganciclovir is currently being evaluated in a global Phase 2 pivotal trial for the treatment of patients with Epstein-Barr virus-positive (EBV</font><font style="color:rgba(0,0,0,1);font-weight:normal;vertical-align:top;font-size:8.04pt;font-family:Calibri;">+</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">) lymphoma.  Viracta has also received United States Food and Drug Administration clearance of an Investigational New Drug application to proceed into a global Phase 1b/2 trial evaluating its combination therapy in patients with EBV</font><font style="color:rgba(0,0,0,1);font-weight:normal;vertical-align:top;font-size:8.04pt;font-family:Calibri;">+</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;"> recurrent or metastatic nasopharyngeal carcinoma and other EBV</font><font style="color:rgba(0,0,0,1);font-weight:normal;vertical-align:top;font-size:8.04pt;font-family:Calibri;">+</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;"> solid tumors. Initiation of this Phase 1b/2 trial is expected in the second half of 2021.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Calibri;">About Nanatinostat</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Calibri;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">Nanatinostat (VRx-3996) is an orally available histone deacetylase (HDAC) inhibitor being developed by Viracta. Nanatinostat is selective for specific isoforms of Class I HDACs, which is key to inducing viral genes that are epigenetically silenced in EBV-associated malignancies. The nanatinostat and valganciclovir combination is being investigated in various subtypes of relapsed/refractory EBV</font><font style="color:rgba(0,0,0,1);font-weight:normal;vertical-align:top;font-size:8.04pt;font-family:Calibri;">+</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">&#160;lymphoma in multiple clinical trials, including a registration-enabling global, multicenter, open-label basket trial.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">		Page | </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Calibri;">About Viracta Therapeutics, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in two Phase 2 clinical trials for EBV-positive lymphoma. Viracta is also pursuing application of its inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">For additional information please visit&#160;</font><font><font style="font-weight:normal;font-size:12.0pt;font-family:Calibri;">www.viracta.com</font></font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Calibri;">Forward-Looking Statements</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">This communication contains &#34;forward-looking&#34; statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, the statement regarding Viracta&#x2019;s belief that regaining the development and commercial rights in China will enable Viracta to expand its global development strategy and has the potential to unlock significant, long-term and unencumbered value to its shareholders; and other statements that are not historical facts.&#160; Risks and uncertainties related to Viracta that may cause actual results to differ materially from those expressed or implied in any forward-looking statement include, but are not limited to: Viracta's ability to successfully enroll patients in and complete its ongoing and planned clinical trials; Viracta's plans to develop and commercialize its product candidates, including all oral combinations of nanatinostat and valganciclovir; the timing of initiation of Viracta's planned clinical trials; the timing of the availability of data from Viracta's clinical trials; previous preclinical and clinical results may not be predictive of future clinical results; the timing of any planned investigational new drug application or new drug application; Viracta's plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of Viracta's product candidates; Viracta's ability to manufacture or supplying nanatinostat, valganciclovir and pembrolizumab for clinical testing; Viracta's ability to identify additional products or product candidates with significant commercial potential; developments and projections relating to Viracta's competitors and its industry; the impact of government laws and regulations; Viracta's ability to protect its intellectual property position; and Viracta's estimates regarding future expenses, capital requirements and need for additional financing in the future.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">These risks and uncertainties may be amplified by the COVID-19 pandemic, which has caused significant economic uncertainty. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption &#34;Risk Factors&#34; and elsewhere in Viracta's reports and other documents that Viracta has filed, or will file, with the SEC from time to time and available at&#160;</font><font><font style="font-weight:normal;font-size:12.0pt;font-family:Calibri;">www.sec.gov</font></font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">The forward-looking statements included in this communication are made only as of the date hereof. Viracta assumes no obligation and does not intend to update these forward-looking statements, except as required by law or applicable regulation.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">		Page | </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:45.345%;"></td>
    <td style="width:54.655%;"></td>
   </tr>
   <tr style="height:12.95pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Investor Relations Contact:</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Viracta Contact:</font></p></td>
   </tr>
   <tr style="height:7.2pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Joyce Allaire</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Dan Chevallard</font></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">LifeSci Advisors</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Chief Operating Officer and Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font><font style="font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">jallaire@lifesciadvisors.com</font></font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(5,99,193,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">dchevallard@viracta.com</font></p></td>
   </tr>
   <tr style="height:7.9pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(212) 915-2569</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(858) 771-4193</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;"> SOURCE Viracta Therapeutics, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">		Page | </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;"> </font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>4
<FILENAME>virx-20210819_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2021-08-23T05:45:54.6831+00:00 -->
<!-- Copyright (c) 2021 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://viracta.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="virx-20210819.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://viracta.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>virx-20210819_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2021-08-23T05:45:54.6432+00:00 -->
<!-- Copyright (c) 2021 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>virx-20210819.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2021-08-23T05:45:54.5267+00:00 -->
<!-- Copyright (c) 2021 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://viracta.com/20210819" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:virx="http://viracta.com/20210819" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="virx-20210819_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="virx-20210819_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:roleType roleURI="http://viracta.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>virx-20210819_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="virx-20210819.xsd" xlink:type="simple"/>
    <context id="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001061027</identifier>
        </entity>
        <period>
            <startDate>2021-08-19</startDate>
            <endDate>2021-08-19</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24"
      id="F_99a448ca-4632-4afe-a3a6-7c3efd7aa1b3">Viracta Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:AmendmentFlag
      contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24"
      id="F_c6547e63-7c8b-43a5-bdbb-c242e5b5cb3d">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24"
      id="F_82bc508a-43ab-4a58-a008-b41d3a6e97ec">0001061027</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24"
      id="F_b2c24b6f-89ae-47ea-b8ab-897f9dcf84a0">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24"
      id="F_fb0b928d-6563-47fd-b1f3-a7a2684dc135">2021-08-19</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24"
      id="F_aa31a73f-20f5-4da3-9186-45e7b54c0a92">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24"
      id="F_3cad98d0-6984-4412-8548-01ef495b85fc">000-51531</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24"
      id="F_8db97ff1-0584-4b07-9ee2-9afee9f1f516">94-3295878</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24"
      id="F_034c6ffd-922c-4189-84d6-7656116b2b43">2533 S. Coast Hwy. 101, Suite 210</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24"
      id="F_1ad26db1-5185-4a4e-a243-f257c2c65bf9">Cardiff</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24"
      id="F_f0db7117-e876-46aa-bcaa-df46b6b3af4a">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24"
      id="F_6b373f51-15bc-40f2-8694-d53d815c3f70">92007</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24"
      id="F_e4d75748-d9d7-4287-8e6b-363498a97a44">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24"
      id="F_daaff47f-11c3-48ac-afd5-7b2f2a609e24">400-8470</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24"
      id="F_6b4f1169-4b8e-48a4-ae41-47e71381c7c7">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24"
      id="F_2f4b2d15-0bd8-473d-9ec2-b11435062021">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24"
      id="F_16917a3e-46d6-4414-9079-3e00b51b964b">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24"
      id="F_418f36d1-7417-4e9f-9f94-6e9e8e1236c6">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24"
      id="F_d99df070-29b0-4674-b5fe-1b71a3df6634">Common Stock,  par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24"
      id="F_1faa20b5-7988-4f69-8a79-841d82155865">VIRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24"
      id="F_1c82aff4-357f-41c4-86d3-1a334d50a202">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24"
      id="F_ac32db22-e2e1-4153-b8b4-a2aaebd80b5e">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140152148481000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Aug. 19, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 19,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Viracta Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001061027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-51531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3295878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2533 S. Coast Hwy. 101, Suite 210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cardiff<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">400-8470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock,  par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VIRX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ ID 74P=!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    " "F0!=3)1UC&^X    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    " "F0!=3F5R<(Q &  "<)P  $P
M        @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( *9
M%U.R[0@%3@0  &$0   8              " @0T(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    " "F0!=3GZ ;\+$"  #B#   #0
M        @ &1#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( *9 %U.7BKL<
MP    !,"   +              "  6T/  !?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( *9 %U,ZJJ+G0 $  #P"   /              "  580  !X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " "F0!=3)!Z;HJT   #X 0  &@
M    @ '#$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" "F0!=399!YDAD!  #/ P  $P              @ &H$@  6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     "0 ) #X"  #R$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="virx-20210819.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://viracta.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="virx-20210819.htm">virx-20210819.htm</File>
    <File>virx-20210819.xsd</File>
    <File>virx-20210819_lab.xml</File>
    <File>virx-20210819_pre.xml</File>
    <File>virx-20210819ex10_1.htm</File>
    <File>virx-20210819ex99_1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "virx-20210819.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "virx-20210819.htm"
     ]
    },
    "labelLink": {
     "local": [
      "virx-20210819_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "virx-20210819_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "virx-20210819.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "virx",
   "nsuri": "http://viracta.com/20210819",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "virx-20210819.htm",
      "contextRef": "C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document And Entity Information",
     "role": "http://viracta.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "virx-20210819.htm",
      "contextRef": "C_9e0da5ae-6b38-4691-b7a8-0f7bd75a1a24",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000950170-21-001535-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-21-001535-xbrl.zip
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M!BSQ1YC%/^HT<RO0U'W&78<KU'(=@QJ&JE''- !FJ@@,U_0<,_"?!YJ?PDA
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M%-_N#KR6WUY9N;_=G=D7W[H\:GD)GWS\Z:@UR(?1Q_\'4$L#!!0    ( *9
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MHBB)HA68*!:23IXT'*2'8%$F-N?(V *N*2<\I83!T 7]##V>!G#)& PL2L$
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M9 <P)2PMV=MQS[2VPAJAZU*SJN'&KC:"E8VN)?7M<OX'4$L#!!0    ( *9
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M4L8)JYL0%%2US&I]W[WKSCE2!BGOM_NK38/^T/_6N?\74$L#!!0    ( *9
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M6Y;%=7O9 0K^#':1]I-Q R.&H9J9]MP^!')ZRT[<S7C'O5TD!A\<A.)FU\1
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M+)ZT=QFD\+#&X:<U;X>NU((=5BO)&UE^P?T1 IZPWK]@(-A(!Y_ X#Z"%8P
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M+FAT;>U<;7/;-A+^W/L5F/::B^<DV;+C-))\F;I.,N>;7)-QVK1?01*44(,
M"X!2E+D??\\"I$1+5F.GML=.-9V.8XIXVY=GG]V%?#3QA7K^-W8T$3S#3W;D
MI5?B^<M?NX-!KW^T&W_%"[OU&T>)R>;AS9(Y/U?B7U][\<%WI<Z$]L.]WMZW
MH]QHWW7RHQCV\7OI1P6W8ZF[WI3#^$!)+;H3(<<3/^SW#N*(G!=2S8<_R4(X
M]J.8L3-3<-T,3HSWIJC'AR6YDF,]M#3)Z.OG1S1'LZ76#O;#@/8")QB86(DQ
MC[[I/]T;'>W2I\^/=LM[?Z[4*&.'=ISPQWL=^J^_$]>8Q36UL057HRL>_^6'
MB4RD9U'5]U$(*985]KI22(S*KBJ#]]+RU'/VTT187HK*R]2Q,\'3WRMIL=67
M'U)5.3D5[(68"F7* EMB7&?LQ!2%L*G$5!^YET:S,UK=L=Q8)O'S6*GN&\L5
MO9E('=^)Z\R9U.QD@H</2>Y?@%=]GD%=QZWB2S3O4'H\2UM&ILV,I?C<&N78
M6)D$QF&CT7@3;(;#9@S93-JR&2O&.*5F)F>:TS-MG.?1"J=<C;E.9:K,5-I&
MZ'=Y. ;MWDM=_U8Y+_/Y%VC%&TYVVYI^>T9;=#, 8X>]XYJ]D&)L.NRX&F-#
M;/^@P_;W]OOLT3<?]O?Z!R/6-L=+E/!90:OVI85B;M?@8=[MR-!AISKM,?;X
M1^XR_ON0O3\]^W6GPS@KK4BE(V\UFC8PGI,+EUS/F8<R!9QVS."AE>MRYPS"
MAA<9*X(^R7\%YO8FXW-XM3:53O&IG\#)$9\GW $#ZI!$CP43B["TQ(\L!J@
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M     '9I<G@M,C R,3 X,3DN:'1M4$L! A0#%     @ ID 74U B^PC[ @
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M,#(Q,#@Q.65X,3!?,2YH=&U02P$"% ,4    " "F0!=3S/RI3K4-  ",5@
M%P              @ %L-0  =FER>"TR,#(Q,#@Q.65X.3E?,2YH=&U02P4&
2      8 !@". 0  5D,

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
